Page 1 of 29

1 Title page

Immunogenicity and Safety of a 14-valent pneumococcal polysaccharide conjugate vaccine 2 (PNEUBEVAX 14TM) administered to 6-8 weeks old healthy Indian Infants: A single blind, 3 4 randomized, active-controlled, Phase-III study Ramesh V Matur¹, Subhash Thuluva¹, Subbareddy Gunneri¹, Vijay Yerroju¹, Rammohan reddy 5 Mogulla¹, Kamal Thammireddy¹, Piyush Paliwal¹, Niranjana S Mahantshetty², Mandyam Dhati 6 Ravi³, S. Prashanth⁴, Savita Verma⁵, Jai Prakash Narayan⁶. 7 Affiliations: ¹Biological E Limited, 18/1&3, Azamabad, Hyderabad – 500 020, Telangana, 8 India; ²KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Department of 9 Pediatrics, Belgaum, Karnataka, India.; ³JSS Hospital, Department of Pediatrics, Mysore, 10 Karnataka India; ⁴Cheluvamba Hospital, Mysore Medical College & Research Institute, Dept. of 11 Paediatrics, Mysore, Karnataka, India; ⁵Pandit Bhagwat Dayal Sharma Post Graduate Institute of 12 Medical Sciences & Hospital, Department of Pharmacology, Rothak, Harvana, India; ⁶Jawahar 13 Lal Nehru Medical College, Kala Bagh, Rajasthan, India. 14 Corresponding Author Name: Ramesh V Matur, Biological E Limited, 18/1&3, Azamabad, 15 Hyderabad – 500 020, Telangana, India, 16 17 **E-mail:** Ramesh.Matur@biologicale.com 18 Funding Support: The study was funded by Biological E Limited, 18/1&3, Azamabad, 19 20 Hyderabad – 500020, Telangana, India 21

Page 2 of 29

22 ABSTRACT

Background: Introduction of pneumococcal conjugate vaccines (PCV) reduced the cases of pneumococcal disease at global level. However, there is an increase in clinical and economic burden of PD from non-PCV serotypes, particularly in pediatric and elder population. In this study, immunogenicity and safety of the BE's 14-valent PCV (PNEUBEVAX 14TM; BE-PCV-14) containing two additional epidemiologically important serotypes (22F and 33F) in comparison to PCV-13 was evaluated in infants.

Methods: This is a pivotal phase-3 single blind randomized active-controlled study conducted at 29 12 sites across India in 6-8 weeks old healthy infants in 6-10-14 weeks dosing schedule to assess 30 31 immunogenic non-inferiority and safety of a candidate BE-PCV-14. In total, 1290 infants were equally randomized to receive either BE-PCV-14 or PCV-13. Solicited local reactions and 32 systemic events, adverse events (AEs), serious AEs (SAEs) and medically attended AEs 33 34 (MAAEs) were recorded. Immunogenicity was assessed by measuring anti-PnCPS IgG concentration and functional antibody titers by opsonophagocytic activity (OPA), one month 35 after completing three dose schedule. Cross protection to serotype 6A offered by serotype 6B 36 37 was also assessed in this study.

38 **Findings**:

The safety profile of BE-PCV-14 was comparable to PCV-13 vaccine. Majority of reported AEs were mild in nature and no severe or serious AEs were reported. Primary immunogenicity objective was met for all 14 serotypes. For the twelve common serotypes non-inferiority to those l2 serotypes in PCV-13 was met. Additional serotypes in BE-PCV-14 (22F and 33F) also met NI criteria as defined by WHO TRS-977. A significant seroconversion, about 69% for serotype 6A was observed even though this antigen was not present in BE-PCV-14. This indicates that

Page **3** of **29**

45	serotype 6B of BE-PCV-14 cross protects serotype 6A. BE-PCV-14 also elicited comparable				
46	serotype specific functional OPA immune responses to all the serotypes in PCV-13.				
47	Interpretations: BE-PCV-14 was found to be safe and induced robust and functional serotype				
48	specific immune responses to all 14 serotypes. All serotype-specific IgG responses were				
49	comparable to those in PCV-13. These findings suggest that BE-PCV-14 can be safely				
50	administered to infants and achieve protection against pneumococcal disease caused by serotypes				
51	covered in the vaccine.				
52	The study was prospectively registered with clinical trial registry of India-				
53	CTRI/2020/02/023129				
54	KEY WORDS: Infants, Pneumococcal disease, Conjugate vaccine, Serotype, Pneumococcal				
55	capsular polysaccharide, Opsonophagocytic activity.				
БC					
50					
57					
58					
59					
60					
61					
62					
63					
64					
65					
66					

Page 4 of 29

67 **INTRODUCTION**

Streptococcus pneumoniae is a gram positive bacterium, causing morbidity and mortality 68 globally in children under 5 years, adults above 50 years and in individuals with comorbidities. It 69 manifests a variety of invasive or noninvasive diseases such as pneumonia, otitis media, 70 nasosinusitis, bacteremia and meningitis ^{1,2}. Most of the deaths are caused by invasive 71 pneumococcal disease (IPD) with reported >300000 deaths worldwide in children under 5 years 72 every year due to pneumonia or meningitis³. In developing countries, case fatality rates may be 73 as high as 50% for meningitis and up to 20% for septicemia. As per a global population-based 74 model in 2015 and as per WHO data, case fatality rates under 5 years' is the highest in India 75 followed by Pakistan, Bangladesh, Sri Lanka and Indonesia with reported incidences over 76 200/100,000 population 4,5 . Although there are more than 95 identified serotypes of S 77 *pneumoniae*, few serotypes are responsible for causing the disease 6 . In addition, in more than 78 30% of cases, pneumococcal bacteria are resistant to one or more antibiotics ⁷. 79

A 23-valent, unconjugated pneumococcal polysaccharide vaccine (PPSV23; Pneumovax® 23, 80 Merck and Co., Inc., NJ) provides only transient protection as it elicits T-cell independent 81 immune responses⁸. Pneumococcal polysaccharide-protein conjugate vaccines (PCVs) 7- and 13-82 valent (PCV-7; Prevenar 7[®]; PCV-13; Prevenar 13[®]; Pfizer, New York), were able to induce T-83 cell dependent immune response against respective serotypes and generate robust functional 84 antibody responses providing long-term protection against IPD across different age groups ⁹⁻¹¹. 85 Introduction of PCVs substantially reduced the burden of IPD worldwide in all age groups ¹². 86 Despite these reductions, one-fourth to one-third of the S. pneumoniae serotypes causing IPD are 87 not covered by currently available PCVs and these serotypes bring about a significant unmet 88 medical need ¹³⁻¹⁵. A study by Balsells, et al. ¹⁶ reported that 42.2% of childhood IPD cases were 89

Page 5 of 29

90 caused by non-vaccine serotypes. So, it is important to include additional serotypes to minimize the burden of IPD. Biological E Limited developed a PCV covering 14 different serotypes 91 (PNEUBEVAX 14TM) including 2 serotypes (22F and 33F) that are not included in PCV-13. 92 93 These two serotypes were reported to be among top 11 predominant non-vaccine serotypes, which accounted for 22% of invasive pneumococcal disease cases in India under-five years ^{17,18}. 94 A recent study ¹⁹, also reported that 22F and 33F as the most prevalent non-PCV13 serotypes 95 causing IPD²⁰. Moreover, these two serotypes are among the first to increase in replacement 96 disease after introduction of PCV-7 and PCV-13 vaccines ¹⁹, ²⁰. Accessibility to PCVs with 97 additional serotypes can be increased when the vaccines are developed in a country such as India 98 that is among countries with the major disease burden. 99

Safety and immunogenicity of BE-PCV-14 was established in phase-1 and phase-2 studies in
healthy adults and toddlers respectively (CTRI/2017/06/008759 and CTRI/2017/11/010387).
Here we report the immunogenicity and safety of BE-PCV-14 in 6-8 weeks old healthy infants
(n=1290) in 6-10-14 weeks dosing schedule and PCV-13 was used as a comparator to
demonstrate the immunogenic non-inferiority.

105 METHODS

106 Study Design and Participants

The phase-3, two arm, single blind, randomized, active-controlled study was conducted between February 2020 and March 2022 in India across 12 sites. Study was designed to evaluate the immunogenic non-inferiority and safety of a BE-PCV-14 administered to 6-8 weeks old healthy infants in 6-10-14 weeks dosing schedule. Participants were equally randomized (1:1) to receive either BE-PCV-14 (test) or PCV-13 (Prevenar 13[®], comparator). In total, 1290 subjects were enrolled into the study (n=645 in BE-PCV-14 arm and n=645 in PCV-13 arm). A dose of 0.5mL

Page 6 of 29

of the study vaccine (BE-PCV-14 or PCV-13) was administered intramuscularly in a three dose
vaccination schedule (3+0) with a 4-weeks interval.

All enrolled subjects (N=1290) were healthy infants with \geq 3300 grams weight at the time of 115 116 screening. None of the subjects received any licensed or investigational pneumococcal vaccine prior to enrollment. Other permitted vaccines included single dose of BCG, hepatitis B, DTwP-117 HepB-Hib (liquid pentavalent), polio and rotavirus vaccines. Informed consent was obtained 118 119 from subjects' parent(s) prior to performing any study specific procedure. Exclusion criteria used were evidence of previous S. pneumoniae infection, use of any investigational or non-registered 120 product (drug or vaccine) -30 days prior to study vaccine administration, history of any 121 neurological disorders, meningitis, or seizures, family history of congenital or hereditary 122 immunodeficiency, history of allergic disease or history of a serious reaction to any prior 123 124 vaccination or known hypersensitivity likely to be exacerbated by any component of the study 125 vaccines. Complete list of eligibility criteria provided as supplementary information.

The study was conducted in accordance with the principles defined in the Declaration of Helsinki, International Conference on Harmonization guidelines (Good Clinical Practices), and the new drug and clinical trial rules, 2019²¹. The investigational review board or ethics committee at each study site approved the protocol.

130 **Randomization and masking:**

Eligible subjects were randomized to receive either BE-PCV-14 or PCV-13 in 1:1 ratio and randomization numbers were assigned using an interactive web-based randomization system (IWRS). Randomization sequence was generated using SAS software (SAS Institute Inc, 100 SAS Campus Drive, Cary, NC 27513-2414, USA).

135 **Procedure**

Page 7 of 29

136	Screening, enrolment, and first dose of primary vaccination was done when infants were 6-8
137	weeks old (visit-1; day 0). Second and third doses of primary vaccination (visit-2; day 28 and
138	visit-3; day 56) and a final follow up immunogenicity visit (visit-4, day 86) took place at four
139	weeks' interval.

An additional time window of +7 days for the second, third, and the fourth visit was permitted toensure subject's visit compliance.

Each 0.5mL of single human dose of BE-PCV-14 (PNEUBEVAX 14TM) contained 3µg of 142 serotype 1 and 2.2µg of each of serotypes 3, 4, 5, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F 143 144 and 4.4µg of serotype 6B polysaccharides conjugated to about 35 µg of non-toxic diphtheria toxin cross-reacting material 197 (CRM₁₉₇) protein and adsorbed onto ≤ 0.75 mg of aluminium 145 phosphate (Al+++). The 13-valent Pneumococcal polysaccharide conjugate vaccine "PCV-13" 146 147 (control vaccine) contained 2.2µg of each of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides, and 4.4 μ g of 6B saccharide, 34 μ g CRM₁₉₇ carrier protein, and 125 μ g aluminum 148 149 as aluminum phosphate adjuvant. Both vaccines were administered in the anterolateral aspect of 150 thigh.

Approximately 5.0 mL of blood was collected at visit-1(day 0) and again at visit-4 (day 86). Anti-PnCPS IgG antibody concentration estimation against each of the 14 vaccine serotypes was performed as per the WHO reference ELISA assay ²² with a minor modification. Cell wall polysaccharide (CWPS) multi was used instead of CWPS and 22F PnPS for pre-absorption to neutralize non-specific antibodies and other common contaminants present in the PnPS coating antigens. Functional antibody responses against all 14 serotypes were assessed by opsonophagocytic activity (OPA) assay, which was performed at WHO pneumococcal serology

Page 8 of 29

reference laboratory (UCL Great Ormond Street, Institute of Child Health, Immuno-biologySection, United Kingdom).

Each vaccinated infant was observed for at least 60 minutes after vaccination to evaluate and treat for any immediate adverse reactions. At each vaccination visit, a diary card was provided to the subject's parent(s)/LAR[s] to record any solicited local/general AE occurring after vaccination for 7 consecutive days (day 0 - day 6). List of solicited local and systemic AEs are provided as supplementary information.

Unsolicited AEs, serious adverse events (SAEs), medically attended adverse events (MAAEs) were recorded until the end of the study. Severity of all AEs was graded as per the common terminology criteria for adverse events (CTCAE V5.0) or division of AIDS (DAIDS) table version 2.0. Brighton collaboration scale was taken for severity grading of fever. All AEs were assessed for relatedness to study vaccine by the investigator.

170 **Outcomes:**

Primary outcome of the study was to demonstrate serotype specific immunogenic non-inferiority 171 172 (NI) of BE-PCV-14 to licensed PCV-13 vaccine one month after the completion of primary vaccination series against 12 common serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 173 174 23F) in terms of number of subjects seroconverted and the ratio of IgG geometric mean 175 concentrations (GMCs). Immunogenic NI for new serotypes 22F and 33F in BE-PCV-14 was demonstrated by comparing immunoglobulin G (IgG) concentrations induced by serotypes 22F 176 and 33F of BE-PCV-14 with one of the PCV-13 serotypes that showed the lowest sero-response. 177 Sero-response or seroconversion rate was defined as proportion of vaccinated infants with 178 serotype specific IgG antibody concentrations of at least $\geq 0.35 \mu g/ml^{23}$. 179

Page 9 of 29

One of the secondary objectives of the study was to assess the immune response in terms of serotype specific opsonophagocytic activity (OPA) in a randomly chosen subset of subjects from the BE-PCV-14 group compared with an equal number of subjects randomly chosen from PCV-13 vaccinated group. Other secondary outcome was to evaluate the safety of BE-PCV-14 in comparison with PCV-13 measured by the incidence rates of reactogenicity events (local reactions and systemic events) and adverse events (AEs).

186 Statistical Analyses

187 Sample size determination:

Sample size estimation was based on the 2-sided 95% confidence interval (CI) for the difference in proportion of subjects achieving a serotype-specific pneumococcal IgG concentration $\geq 0.35 \mu g/mL$ in each vaccine group. After study completion, a two-sided 95% confidence interval for the true difference between the two proportions was constructed. The lower bound of the confidence interval was to lie entirely on the positive side of the -10% points margin to demonstrate non-inferiority.

194 Data from the phase-II safety and immunogenicity study in 12 to 23 months old children 195 conducted in India (CTRI/2017/11/010387) was used to support sample size estimation. The 196 power was computed for an anticipated test vaccine group proportion of 92.33% within the non-197 inferiority margin set. The significance level of the test was targeted at 0.025. Accordingly, sample sizes of 581 in each group was estimated to achieve 90% power and to detect a non-198 199 inferiority margin difference between the group proportions of -0.10. An anticipated, not more 200 than 10% dropout rate was built-in to the sample size. Therefore, the overall sample size required 201 was 645 infants per group to obtain 581 evaluable infants per group at the end of the study.

202 Statistical analyses

Page 10 of 29

203 All demographic and baseline characteristics of both the groups were presented using intend-to 204 treat (ITT) population, defined as all subjects randomized into the study. The data was analyzed 205 by summary statistics. All subjects who received at least one dose of the study vaccine were 206 included in the safety analysis and the datawas summarized descriptively. For continuous variables n, mean, standard deviation, median and range (minimum, maximum) have been 207 presented. For categorical data, frequencies were computed. All reported adverse events during 208 209 the entire study period were summarized by calculating frequencies and listed per subject 210 including severity and relationship (causality).

The number and percentage of subjects with AEs were presented by system organ class and preferred term. All medically attended AEs reported during the study were listed and analyzed for expectedness and causality. Two-sided 95% exact confidence intervals were calculated for all the occurrence rates of reported AEs and SAEs during the study. All AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRATM; version 25.1) coding dictionary and concomitant medications have been coded using the World Health Organization (WHO) Drug Dictionary, March 2022.

Immunogenicity assessment was based on the per-protocol population defined as the vaccinated
subjects whose blood samples were available for immunogenicity analysis at both baseline and
day 86 (visit-4). Non-inferiority of serotype specific immune responses induced by BV-PCV-14
against PCV-13 was assessed by one of the below two criteria as per the WHO defined criteria²³.
By measuring difference in proportion of subjects seroconverted to achieve serotype

specific anti-PnCPS IgG concentration $\ge 0.35 \ \mu$ g/ml between BE-PCV-14 and PCV-13. The lower limit of 95% CI for the difference in proportion subjects seroconverted between BE-PCV-14 and PCV-13 should be above the minus 10% points.

Page 11 of 29

226	2. By assessing the IgG GMC ratio (BE-PCV-14/PCV-13) along with its two sided 95%
227	confidence interval. Non- inferiority was considered achieved if the ratio of lower limit
228	of two sided 95% CI (test /control group) was above the pre-specified margin of 0.5.
229	For two new serotypes 22F and 33F which were not part of PCV-13, non-inferiority was
230	assessed by comparing with any serotype in the PCV-13 group that achieved the lowest
231	percentage of $\geq 0.35 \mu g/ml$ IgG GMC. For serotype 6A, which was not in BE-PCV-14 but present
232	in PCV-13, a \geq 2-fold increase in the 6A specific geometric mean concentrations (GMCs) above
233	pre-vaccination levels was assessed as an exploratory outcome. Proportion of subjects achieving
234	\geq 4-fold rise in anti-PnCPS IgG antibody concentrations from baseline and geometric mean fold
235	rise (GMFR) along with their 2-sided 95% CI against each of the vaccine serotype was
236	calculated.
237	As a secondary outcome, proportion of subjects achieving a serotype-specific OPA titre≥1:8 post
238	vaccination was assessed along with 2-sided 95% confidence. Serotype specific OPA geometric

240 vaccine groups was evaluated.

A reverse cumulative distribution (RCD) curve of anti-PnCPS antibody concentrations and OPA GMT titers by serotype of BE-PCV-14 and PCV-13 were plotted for all common vaccine serotypes in both groups.

mean titres (GMT) along with their ratios and GMFR against 12 common serotypes in both

244 **RESULTS**

239

A total of 1290 subjects were screened and randomly assigned to receive either BE-PCV-14(n=645) or PCV-13 (n=645) study vaccine. Out of 1290 subjects, 1267 (98.2%) subjects (641 in BE-PCV-14 arm and 626 in PCV-13 arm) completed all the visit specific procedures and were included in the immunogenicity (anti-PnCPS IgG antibody concentration) analysis. In total, 22

Page 12 of 29

249 (1.7%) subjects were dropouts. Subject disposition with reason for dropout from the study was 250 presented in Figure 1. Safety analyses were performed in all enrolled subjects (n=1290) whereas 251 immunogenicity (per-protocol population) was completed in 1267 subjects. One subject was 252 excluded from per-protocol population due to insufficient serum sample and the rest (n=22) were dropouts. Demographics of intention-to-treat population were presented in Table 1. Age of the 253 subjects and male to female ratio was comparable in both BE-PCV-14 and PCV-13 arms. 254 255 Summary of other eligible vaccinations received by study subjects was presented in 256 Supplementary Table 1.

257 The proportion of subjects with anti-PnCPS IgG antibody concentrations equal to or above the 258 protective threshold $\geq 0.35 \mu$ g/mL (primary outcome) at day 86 in BE-PCV-14 (n=641) group was in the range of 76.3% (serotype6B) to 99.7% (serotype 14) and in the PCV-13 (n=626) group, 259 260 the response rate was in the range of 77% (serotype 3) to 100% (serotype14) for 12 common serotypes. The lower limit of 95% CI for the difference in proportion of subjects seroconverted 261 262 between BE-PCV-14 and PCV-13 was above the minus 10% points for all the 12 common 263 serotypes (serotype 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and all of them met predefined NI criteria. The distributions in serotype-specific IgG concentrations for 12 common 264 serotypes in both vaccine groups were similar, as shown by the reverse cumulative distribution 265 curves (Figure 3). 266

Seroresponse rates for serotype 22F (94.1%) and 33F (73.2%) that are present only in BE-PCV14 group were compared with the lowest performing serotype 3 (77.0%) in PCV-13 group.
Defined NI criteria was met for both serotypes 22F and 33F (Figure 2a).

For IgG geometric mean concentrations, NI criteria was achieved for all 12 common serotypes and for additional 22F and 33F serotypes (Figure 2b). The lower bound of the 95% CI for GMC

Page 13 of 29

272	ratio was in the range of 0.67 (serotype 1) to 1.10 (serotype 3) for 12 common serotypes present
273	in BE-PCV-14 and PCV-13. For serotype 3 and serotype 14, lower bound 95% CI was 1.10 and
274	1.01 respectively, indicating that BE-PCV-14 induces strong immune response compared to
275	PCV-13. Serotypes 22F and 33F, which are not present in PCV-13, the lower bound of the 95%
276	CI for GMC ratio was 5.26 and 1.82 respectively (Figure 2b), when compared to the lowest
277	performing serotype in PCV-13 (serotype 3).

The proportion of subjects achieving a serotype-specific OPA titer \geq LLOQ (\geq 1:8) at day 86 were

in the range of 63.64% (serotype-1) to 98.43% (serotype-22F) in BE-PCV-14 group and 64.43%

280 (serotype-1) to 98.46% (serotype-7F and serotype-23F) in PCV-13 group. Overall, the OPA

281 GMTs were comparable among all common serotypes in both vaccinated groups (Table 2).

The additional serotypes 22F and 33F in BE-PCV-14 vaccine had 15.16 and 16.91-fold rise in OPA GMTs respectively at day 86 compared to pre-vaccination levels, signifying that both the additional serotypes can induce high levels of protective functional antibodies in vaccinated infants (Table 2). The proportion of subjects achieving \geq 4-fold increase in anti-PnCPS IgG antibody concentrations at day 86 from baseline is presented in Table 3.

BE-PCV-14 vaccine has serotype 6B and no serotype 6A. In this study, we tested the cross protection against serotype 6A, assessed by a \geq 2-fold increase in the 6A specific IgG antibody concentrations and the OPA antibody titers above the pre-vaccination levels. There was 2.4-fold (pre-vaccination GMC: 0.45 and post-vaccination GMC: 1.08) and 7.64-fold (OPA GMT were 16.59 and 134.50 for pre- and post-vaccination, respectively) increase in serotype 6A specific IgG and OPA antibody titers respectively (Table 4). Our data on serotype 6A specific 69.7% seroconversion and 2.4-fold rise in GMC in BE-PCV-14 vaccinated infants along with functional

Page 14 of 29

antibody titers (OPA) GMFR of 7.64 fold strongly suggests that the serotype 6B confers
significant immunological cross protection against serotype 6A.

296 The current study demonstrated that BE's 14-valent pneumococcal polysaccharide conjugate 297 vaccine, administered in a 3-dose schedule (6-10-14 weeks), was safe, immunogenic and non-

inferior to PCV-13 for the 12 common serotypes.

Among all vaccinated infants (n=1290), 175/645 (27.1%) subjects and 178/645 (27.6%) subjects 299 300 reported at least one adverse event in BE-PCV-14 and PCV-13 groups respectively. All the reported adverse events were generally mild and only very few cases were moderate in their 301 intensity. Majority of the reported adverse events were solicited in nature and related to the study 302 vaccine. Overview of the reported AEs including solicited and unsolicited AEs were presented in 303 Table 5. Summary of AEs by system organ class (SOC) and preferred term (PT) were shown in 304 305 Table 6. No severe or serious AEs were reported in either of the vaccine groups. Overview of AEs by severity grade and causality to the study vaccine were presented in Table 7. Summary of 306 307 local, solicited systemic and unsolicited AEs by SOC and PT were presented in Supplementary 308 Table 2, 3 and 4. No clinically significant changes overtime were noted in the vital signs. The AEs observed and physical examination results did not indicate any safety issues of concern. 309 Overall, the safety profile of BE-PCV-14 was comparable to the control vaccine PCV-13 in 310 311 terms of AE rates, related AE rates and medically attended AEs and found to be safe and well tolerated. 312

313 **DISCUSSION**

In this phase-3 trial, immunogenic non-inferiority, safety, and reactogenicity of a candidate BE-PCV-14 vaccine administered to 6-8 weeks old healthy infants in 6-10-14 weeks dosing schedule was evaluated. Robust and functional immune responses were elicited by BE-PCV-14 one month

Page 15 of 29

after the third vaccination dose. Primary basis for NI comparison and licensure decisions were based on reaching IgG concentrations $\geq 0.35 \mu g/ml$ for all vaccine specific serotypes in the new vaccine and the licensed comparator. In accordance with WHO TRS 977 guidelines ²³, all 12 common serotypes in BE-PCV-14 met the non-inferiority criteria with those serotypes in PCV-13 in terms of both seroconversion rates (percentage of subjects with IgG $\geq 0.35 \mu g/ml$) and GMC ratios (≥ 0.5). Both BE-PCV-14 and PCV-13 generated comparable functional immune responses

323 (OPA titres), similar to IgG response.

324 In the current study, we evaluated the cross-protection offered by serotype 6B against serotype 325 6A in BE-PCV-14 vaccinated group. Serotype 6A and 6B have high structural similarity of polysaccharide ^{24,25}. Therefore, it was expected that the immune responses induced by serotype 326 6B would provide at least partial cross-protection against serotype 6A in humans. An earlier 327 328 study reported that PCV-13 elicits cross-functional opsonophagocytic killing responses in humans to serotypes not directly covered by the vaccine 26 . In this study, cross-protection was 329 assessed by a \geq 2-fold increase in the 6A specific IgG antibody concentrations and the OPA 330 331 antibody titers above the pre-vaccination levels. We found 2.4-fold and 7.64-fold increase in IgG GMC and OPA titers respectively, against serotype 6A in BE-PCV-14 vaccinated subjects, 332 suggesting that BE-PCV-14 vaccine can offer protection against serotype 6A even though this 333 serotype antigen is not present in BE-PCV-14. The serotype 6A cross protective functional 334 immune response elicited by BE-PCV-14 is notably robust and strong when compared to another 335 10-valent PCV as described elsewhere ²⁷. This clearly indicates that serotype 6B in BE-PCV-14 336 337 affords significant cross protection to serotype 6A. Our results are consistent with previous studies, where it was shown that 23-valent polysaccharide vaccine lacking serotype 6A and 338 carrying serotype 6B elicited cross-functional immune responses against serotype $6A^{28,29}$. 339

Page 16 of 29

340 Vaccine effectiveness (VE) against IPD was established in pediatric population for PCV-13 specific serotypes and it was found to be around 55% ³⁰. Breakthrough IPD was mainly caused 341 by serotype 3 and 19A in PCV-13 vaccinated children. Excluding serotype 3 and 19A, VE of 342 PCV-13 against rest of the vaccine serotypes was reported to be 89% ³⁰. BE-PCV-14 was non-343 inferior to PCV-13 for all shared serotypes and against 2 unique serotypes (22F and 33F) when 344 compared against lowest performing serotype 3 from PCV-13. Importantly, 83.5% of BE-PCV-345 346 14 vaccinated children seroconverted against serotype 3 while 77% seroconverted to serotype 3 in PCV-13 group. Several studies worldwide have shown that substantial proportion of 347 348 pneumococcal disease is caused by non-vaccine serotypes, predominantly by serotype 22F (13.4%) and 33F (21%)^{19,31,32}. Another 15 valent PCV carrying these two serotypes was shown 349 to induce serotype 22F and 33F immune response when compared to PCV-13³³. Similarly, the 350 351 present study also demonstrates that BE-PCV-14 elicited serotype specific (22F and 33F) superior immune responses (Figure 2b). 352

353 BE-PCV-14 containing 12 common serotypes and 22F and 33F serotypes along with cross 354 protection to serotype 6A can protect the susceptible population against pneumococcal disease 355 and may also provide herd immunity.

One limitation of the current study is that it is conducted in only Indian infant population and need to conduct similar studies in other regions. However, based on the VE and post marketing experience with PCV-13 across different geographical regions, it is likely that BE-PCV-14 will have similar effectiveness across regions.

In conclusion, BE-PCV-14 was safe, well tolerated and showed comparable safety profile to that of PCV-13. BE-PCV-14 elicited immune responses non-inferior to PCV-13 in infants for all 12 common serotypes. Statistical NI was also met for two new serotypes 22F and 33F in BE-PCV-

Page 17 of 29

363	14 vaccine. BE-PCV-14 also induced cross protective antibodies against serotype 6A. These data
364	support BE-PCV-14 protection against 14 pneumococcal serotypes and potential benefit against
365	serotype 6A.

366

367

368

369 Acknowledgement

We are thankful to all the study participants, the principal investigators, and the study staff at all 370 371 the clinical sites. We are thankful to all the study participants, the principal investigators, and the 372 study staff at all the clinical sites. The authors would like to thank Scientific Advisory Board 373 (SAB) and the Management of Biological E Limited for their support and valuable guidance. All authors wish to express their appreciation and gratitude for all front-line healthcare workers. 374 Development of this vaccine would not have been possible without the efforts of R&D team, 375 376 manufacturing, quality control, quality assurance and regulatory teams at Biological E. We 377 would also like to thank the members of the DSMB for safety monitoring of the study data. Authors would like to thank Dr. Pothakamuri Venkata Suneetha for her valuable support in 378 drafting, reviewing and finalizing the manuscript, and Mr. Kalyan Kumar P, Mr. Raju 379 380 Esanakarra & Mr. Naga Ganesh B for clinical site management and monitoring.

381 **Conflicts of Interest:**

RVM, ST, SG, VY, RM, KT and PP are employees of Biological E Limited and they do not have
any stock options or incentives. All the other participating authors declare no conflicts of
interest.

385 Data Sharing Agreement

Page 18 of 29

- 386 Study data presented in the manuscript can be made available upon request and addressed to the
- 387 corresponding author Dr. Ramesh V Matur at his email: Ramesh.Matur@biologicale.com

Page 19 of 29

389 **REFERENCES**

- Publication WHO. Pneumococcal vaccines WHO position paper 2012 recommendations. *Vaccine* 2012; **30**(32): 4717-8.
- Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. *Clin Microbiol Infect* 2014; 20 Suppl 5: 45-51.
- 394 3. Wahl B, O'Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and 395 Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, 396 regional, and national estimates for 2000-15. *Lancet Glob Health* 2018; **6**(7): e744-e57.
- 4. Kolhapure S, Yewale V, Agrawal A, Krishnappa P, Soumahoro L. Invasive
 Pneumococcal Disease burden and PCV coverage in children under five in Southeast Asia:
 implications for India. *J Infect Dev Ctries* 2021; 15(6): 749-60.
- Bravo LC, Asian Strategic Alliance for Pneumococcal Disease Prevention Working G.
 Overview of the disease burden of invasive pneumococcal disease in Asia. *Vaccine* 2009;
 27(52): 7282-91.
- Geno KA, Gilbert GL, Song JY, et al. Pneumococcal Capsules and Their Types: Past,
 Present, and Future. *Clin Microbiol Rev* 2015; 28(3): 871-99.
- 405 7. ANTIBIOTIC RESISTANCE THREATS IN THE UNITED STATES. 2019.
 406 <u>www.cdc.gov/DrugResistance/Biggest-Threats.html</u>.
- 8. Niederman MS, Folaranmi T, Buchwald UK, Musey L, Cripps AW, Johnson KD.
 Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and
 noninvasive pneumococcal disease and related outcomes: a review of available evidence. *Expert Rev Vaccines* 2021; 20(3): 243-56.
- 9. Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain
 polysaccharide vaccines have divergent effects on antigen-specific B cells. *J Infect Dis* 2012;
 205(9): 1408-16.
- Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal
 conjugate vaccination in invasive pneumococcal disease incidence and mortality. *Clin Infect Dis*2014; **59**(8): 1066-73.
- 417 11. McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-Valent Pneumococcal
 418 Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US
 419 Adults: A Test-Negative Design. *Clin Infect Dis* 2018; **67**(10): 1498-506.
- 420 12. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal
 421 disease in the era of conjugate vaccine. *J Infect Dis* 2010; **201**(1): 32-41.
- 422 13. Tomczyk S, Lynfield R, Schaffner W, et al. Prevention of Antibiotic-Nonsusceptible
- Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. *Clin Infect Dis* 2016; **62**(9): 1119-25.
- 425 14. Vadlamudi NK, Chen A, Marra F. Impact of the 13-Valent Pneumococcal Conjugate
 426 Vaccine Among Adults: A Systematic Review and Meta-analysis. *Clin Infect Dis* 2019; **69**(1):
 427 34-49.
- 428 15. Wantuch PL, Avci FY. Invasive pneumococcal disease in relation to vaccine type
 429 serotypes. *Hum Vaccin Immunother* 2019; **15**(4): 874-5.
- 430 16. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus
- 431 pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and
- 432 meta-analysis. *PLoS One* 2017; **12**(5): e0177113.

Page 20 of 29

2019.

I7. Jaiswal N, Singh M, Das RR, et al. Distribution of serotypes, vaccine coverage, and
antimicrobial susceptibility pattern of Streptococcus pneumoniae in children living in SAARC
countries: a systematic review. *PLoS One* 2014; **9**(9): e108617.

- 18. Manoharan A, Manchanda V, Balasubramanian S, et al. Invasive pneumococcal disease
 in children aged younger than 5 years in India: a surveillance study. *Lancet Infect Dis* 2017;
 17(3): 305-12.
- 439 19. Amin-Chowdhury Z, Groves N, Sheppard CL, et al. Invasive pneumococcal disease due 440 to 22F and 33F in England: A tail of two serotypes. *Vaccine* 2021; **39**(14): 1997-2004.
- Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing
 invasive pneumococcal disease in England and Wales, 2000-17: a prospective national
 observational cohort study. *Lancet Infect Dis* 2018; **18**(4): 441-51.
- 444 21. NewDrugs_CTRules_2019.
- 445 https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-
- 446 documents/NewDrugs_CTRules_2019.pdf.
- Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for
 quantitation of human antibodies to pneumococcal polysaccharides. *Clin Diagn Lab Immunol*2003; **10**(4): 514-9.
- 450 23. Standardization WECoB. Recommendations to assure the quality, safety and efficacy of
 451 pneumococcal conjugate vaccines. 2013. <u>https://cdn.who.int/media/docs/default-</u>
 452 source/biologicals/vaccine-
- 453 standardization/pneumococcus/trs_977_annex_3.pdf?sfvrsn=344f81e_3&download=true.
- 454 24. Bratcher PE, Park IH, Hollingshead SK, Nahm MH. Production of a unique 455 pneumococcal capsule serotype belonging to serogroup 6. *Microbiology (Reading)* 2009; **155**(Pt 456 2): 576-83.
- Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of
 a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. *J Clin Microbiol*2007; 45(4): 1225-33.
- 26. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent
 pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing
 responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. *Vaccine* 2011; 29(41):
 7207-11.
- Clarke E, Bashorun A, Adigweme I, et al. Immunogenicity and safety of a novel tenvalent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3,
 randomised, double-blind, non-inferiority trial. *Lancet Infect Dis* 2021; 21(6): 834-46.
- Yu X, Gray B, Chang S, Ward JI, Edwards KM, Nahm MH. Immunity to cross-reactive
 serotypes induced by pneumococcal conjugate vaccines in infants. *J Infect Dis* 1999; **180**(5):
 1569-76.
- 470 29. Kim HW, Lee S, Kim KH. Serotype 6B from a pneumococcal polysaccharide vaccine
 471 induces cross-functional antibody responses in adults to serotypes 6A, 6C, and 6D. *Medicine*472 (*Baltimore*) 2016; **95**(37): e4854.
- 30. Ricketson LJ, Bettinger JA, Sadarangani M, Halperin SA, Kellner JD, Canadian
 Immunization Monitoring Program AI. Vaccine effectiveness of the 7-valent and 13-valent
 pneumococcal conjugate vaccines in Canada: An IMPACT study. *Vaccine* 2022; 40(19): 273340.

Page 21 of 29

477 478	31. Owusu-Edusei K, Deb A, Johnson KD. Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine
479	Serotypes in the USA Infect Dis Ther 2022: 11(3): 987-99
100	22 Demozuk WH Martin I Griffith A at al Serotype distribution of invasive Streptococcus
400	52. Demozuk will, Martin I, Olimiti A, et al. Serotype distribution of invasive sueptococcus
481	pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine,
482	2010-2012. Can J Microbiol 2013; 59 (12): 778-88.
483	33. Banniettis N, Wysocki J, Szenborn L, et al. A phase III, multicenter, randomized, double-
484	blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity
485	of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in
486	healthy infants, children, and adolescents (PNEU-PLAN), Vaccine 2022; 40(44); 6315-25.
487	
100	
400	
489	
490	
491	
492	
493	
494	
495	
496	
497	
498	
190	
500	
500	
501	
502	
503	
504	
505	
506	
507	
508	
509	
510	
511	
512	
512	
517	
514	
515	
210	
51/	
518	
519	
520	
521	
522	

- 523
- 524
- 525
- 526 Tables:

527 **TABLE 1: Demographic characteristics of study participants**

Parameter/	BE-PCV-14	PCV-13	Overall	
Statistics/Category	(N=645)	(N=645)	(N=1290)	
Age (Days)				
N1	645	645	1290	
Mean	48.3	48.3	48.3	
SD	3.75	3.69	3.72	
Median	48.0	48.0	48.0	
Range (Min: Max)	(42.0:56.0)	(42.0:56.0)	(42.0:56.0)	
Gender, N1 (%)				
Male	342 (53.0%)	365 (56.6%)	707(54.8%)	
Female	303 (47.0%)	280 (43.4%)	583(45.2%)	
Height (Cms)				
N1	645	645	1290	
Mean	52.0	52.0	52.0	
SD	3.76	4.03	3.89	
Median	51.4	51.2	51.3	
Range (Min: Max)	(40.0:69.0)	(41.0:72.0)	(40.0:72.0)	
Weight (Gms)				
N1	645	645	1290	
Mean	4162.9	4165.7	4164.3	
SD	526.85	526.44	526.44	
Median	4100.0	4100.0	4100.0	
Range (Min: Max)	(3300.0:6000.0)	(3300.0:6300.0)	(3300.0:6300.0)	
Nationality, N1 (%)				
Indian	645 (100.0%)	645 (100.0%)	1290(100.0%)	
BMI				
N1	645	645	1290	
Mean	15.5	15.5	15.5	
SD	2.19	2.31	2.25	
Median 15.6		15.7	15.7	
Range (Min: Max)	(8.0:25.0)	(8.0:26.5)	(8.0:26.5)	

Note: Percentages were calculated using respective column header count as denominator.

Page 23 of 29

529

530 Table 2: Summary of serotype-specific OPA titer ≥LLOQ (≥1:8) in terms of sero-

531 conversion rates, GMTs and fold rise.

					Percen	tage of		
					subjects	with at		
		_			least 4 fo	old rise in		
	OPA sero-co	onversion			OPA GN	1Ts post		
Serotype	rate	9	ОРА	GMTs	vaccir	nation	GN	1FR
			BE-PCV-		BE-PCV-		BE-PCV-	
	BE-PCV-14	PCV-13	14	PCV-13	14	PCV-13	14	PCV-13
Serotype 1	63.64	64.43	23.21	19.94	45.99	42.78	3.81	3.32
Serotype 3	71.81	79.58	59.6	63.01	62.77	61.26	9.97	9.86
Serotype 4	93.68	91.75	426.67	626.04	73.16	73.71	25.92	52.55
Serotype 5	80.73	84.1	66.47	78.17	60.94	66.67	8.95	11.61
Serotype 6B	88.48	88.21	990.66	918.24	70.68	68.72	26.32	27.9
Serotype 7F	97.4	98.46	1023.16	1156.95	71.35	76.92	14.56	19.97
Serotype 9V	97.92	97.94	856.81	746.44	78.65	72.16	24.18	27.22
Serotype 14	95.81	97.44	1951.14	1272.2	61.78	61.03	16.85	13.37
Serotype 18C	93.23	94.36	460.7	561.01	63.02	64.1	15.89	23.39
Serotype 19A	95.83	95.9	394.65	451.18	68.75	76.41	17.57	22.2
Serotype 19F	94.79	92.31	604.3	439.94	83.33	79.49	34.88	26.39
Serotype 23F	97.37	98.46	768.79	995.13	68.42	73.85	16.77	27.8
Serotype 22F	98.43	NA	691.6	NA	61.26	NA	15.16	NA
Serotype 33F	94.18	NA	1859.67	NA	60.85	NA	16.91	NA

532

533

535

536 Table 3: Proportion of subjects achieving ≥4-fold increase in anti-PnCPS IgG antibody

537 concentrations

Anti-PnCPS IgG against each of the vaccine serotype post	BE-PCV14 (N=641)	PCV-13 (N=626)
vaccination (Day 86)	N1 (%) [95% CI]	N1 (%) [95% CI]
Serotype 1	394 (61.5%) [57.58:65.25]	441 (70.4%) [66.70:74.00]
Serotype 3	299 (46.6%) [42.73:50.59]	253 (40.4%) [36.54:44.38]
Serotype 4	241 (37.6%) [33.83:41.48]	294 (47.0%) [43.00:50.96]
Serotype 5	388 (60.5%) [56.63:64.34]	358 (57.2%) [53.21:61.10]
Serotype 6B	341 (53.2%) [49.25:57.12]	324 (51.8%) [47.76:55.74]
Serotype 7F	455 (71.0%) [67.30:74.47]	463 (74.0%) [70.34:77.36]
Serotype 9V	422 (65.8%) [62.02:69.50]	390 (62.3%) [58.37:66.11]
Serotype 14	172 (26.8%) [23.44:30.44]	157 (25.1%) [21.73:28.67]
Serotype 18C	230 (35.9%) [32.16:39.73]	243 (38.8%) [34.98:42.76]
Serotype 19A	212 (33.1%) [29.44:36.87]	230 (36.7%) [32.95:40.65]
Serotype 19F	410 (64.0%) [60.11:67.69]	419 (66.9%) [63.09:70.61]

Page 25 of 29

Anti-PnCPS lgG against each of the vaccine serotype post	BE-PCV14 (N=641)	PCV-13 (N=626)
vaccination (Day 86)	N1 (%) [95% Cl]	N1 (%) [95% Cl]
Serotype 23F	362 (56.5%)	371 (59.3%)
	[52.54:60.35]	[55.30:63.14]
Note: Percentage was calculated using 95% CI for was calculated using Cloppe	g respective header count as de er Pearson Method .	nominator

Page 26 of 29

Table 4: Serotype-6A specific IgG and OPA immune responses:

ST-6A IgG GMC (N=1290)	Pre-Vac	Post-Vac	GMFR	ST-6A OPA GMT (N=386)	Pre-Vac	Post-Vac	GMFR
BE-PCV- 14 (n=645)	0.448	1.075	2.4	BE- PCV14 (n=192)	16.59	134.50	7.64
PCV-13 (n=645)	0.446	1.906	4.27	PCV-13 (n=194)	19.20	690.63	37.35

Page 27 of 29

568

569 Table 5: Overview of AEs- solicited and unsolicited AEs

Category	BE-PCV-14	PCV-13		
N1 (%) [95% Cl] n	(N=645)	(N=645)		
	175 (27.1%)	178 (27.6%)		
Overall AES	[23.73:30.74] 355	[24.18:31.22] 353		
Serious AEs	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0		
Severe AEs	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0		
	137 (21.2%)	144 (22.3%)		
LOCALAES	[18.14:24.60] 235	[19.17:25.74] 251		
	70 (10.9%)	63 (9.8%)		
Systemic AES	[8.56:13.51] 118	[7.59:12.32] 101		
Medically Attended AEs	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0		
	4 (0.6%)	4 (0.6%)		
Als within 60 minutes postvac	[0.17:1.58] 6	[0.17:1.58] 5		
	174 (27.0%)	178 (27.6%)		
AES within 7 days postvac	[23.59:30.58] 354	[24.18:31.22] 352		
	115 (17.8%)	109 (16.9%)		
Als between Day 0 to Day 28	[14.95:21.01] 207	[14.09:20.02] 190		
	61 (9.5%)	73 (11.3%)		
Als between Day 28 to Day 56	[7.31:11.98] 93	[8.98:14.02] 110		
Also between Day E6 to Day 86	46 (7.1%)	41 (6.4%)		
Als between Day 56 to Day 86	[5.27:9.40] 55	[4.60:8.52] 53		
	174 (27.0%)	178 (27.6%)		
Any solicited AES	[23.59:30.58] 353	[24.18:31.22] 352		
Any Uncolligited AEs	2 (0.3%)			
Any Unsoluted Aes	[0.04:1.12] 2	1(0.2%)[0.00:0.86]1		

Note: Percentages were calculated using respective column header group count as denominator.

95% CI was calculated by Clopper-Pearson Method.

 $N_1 \colon Subject\ Count,\ N \colon Subject\ Count,\ N \colon Sample\ Size,\ n \colon Event\ Count$

General Note:

• All AE's were represented as: Subject count (Percentage of subjects) [95% CI] Event Count.

• Solicited Local and Systemic AEs were recored during 7 days (Day 0 - Day 6) after the vaccination.

• Unsolicited adverse event reported at any time, until 28 days after the vaccination.

570

574 Table 6: Summary of AEs by SOC and PT

SOC/PT, N1 (%) [95% Cl] n	BE-PCV-14 (N=645)	PCV-13 (N=645)	
Overall	175 (27.1%) [23.73:30.74] 355	178 (27.6%) [24.18:31.22] 353	
Gastrointestinal disorders	9 (1.4%) [0.64:2.63] 12	5 (0.8%) [0.25:1.80] 8	
Abdominal pain	1 (0.2%) [0.00:0.86] 1	0 (0.0%) [NE] 0	
Diarrhoea	6 (0.9%) [0.34:2.01] 8	2 (0.3%) [0.04:1.12] 3	
Vomiting	3 (0.5%) [0.10:1.35] 3	4 (0.6%) [0.17:1.58] 5	
General disorders and administration site conditions	169 (26.2%) [22.85:29.78] 329	173 (26.8%) [23.44:30.42] 333	
Injection site erythema	33 (5.1%) [3.55:7.11] 38	36 (5.6%) [3.94:7.64] 44	
Injection site induration	9 (1.4%) [0.64:2.63] 13	13 (2.0%) [1.08:3.42] 18	
Injection site pain	93 (14.4%) [11.80:17.37] 133	98 (15.2%) [12.51:18.20] 131	
Injection site swelling	44 (6.8%) [5.00:9.05] 51 48 (7.4%) [5.54:9.75]		
Irritability Postvaccinal	25 (3.9%) [2.52:5.67] 41	21 (3.3%) [2.03:4.93] 31	
Pyrexia	42 (6.5%) [4.73:8.70] 53	40 (6.2%) [4.47:8.35] 51	
Metabolism and nutrition disorders	8 (1.2%) [0.54:2.43] 9	6 (0.9%) [0.34:2.01] 10	
Decreased appetite	8 (1.2%) [0.54:2.43] 9	6 (0.9%) [0.34:2.01] 10	
Nervous system disorders	2 (0.3%) [0.04:1.12] 4	1 (0.2%) [0.00:0.86] 2	
Somnolence	2 (0.3%) [0.04:1.12] 4	1 (0.2%) [0.00:0.86] 2	
Respiratory, thoracic and mediastinal disorders	1 (0.2%) [0.00:0.86] 1	0 (0.0%) [NE] 0	
Cough	1 (0.2%) [0.00:0.86] 1	0 (0.0%) [NE] 0	

95% CI were calculated by Clopper -Pearson Method.

N1: Subject Count, N: Sample Size, n: Event Count

General Note:

• All AE's were represented as: Subject count (Percentage of subjects) [95% CI] Event Count.

575

576

577

578

Page 29 of 29

Table 7: Overview AEs by Severity & Causality

Category	BE-PCV-14	PCV-13	
N1 (%) [95% Cl] n	(N=645)	(N=645)	
Number of subjects with at least	175 (27.1%)	178 (27.6%)	
one AE	[23.73:30.74] 355	[24.18:31.22] 353	
Number of subjects with at least one SAE	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	
Number of subjects with at least one MAAE	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	
Severity			
N 4 H - I	174 (27.0%)	177 (27.4%)	
Ivilia	[23.59:30.58] 343	[24.03:31.06] 338	
	6 (0.9%)	10 (1.6%)	
Moderate	[0.34:2.01] 12	[0.75:2.83] 15	
Severe	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	
Life-threatening	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	
Causality			
Certain 	61 (9.5%)	65 (10.1%)	
	[7.31:11.98] 79	[7.86:12.66] 79	
	73 (11.3%)	68 (10.5%)	
Probable	[8.98:14.02] 84	[8.28:13.17] 77	
Descible	48 (7.4%)	53 (8.2%)	
Possible	[5.54:9.75] 185	[6.22:10.61] 194	
	5 (0.8%)	3 (0.5%)	
Officery	[0.25:1.80] 6	[0.10:1.35] 3	
Unrelated	1 (0.2%)	0 (0.0%) [NE] 0	
	[0.00:0.86] 1		
Unclassifiable	0 (0.0%) [NE] 0	0 (0.0%) [NE] 0	
Related (Certain/Probable/	173 (26.8%)	177 (27.4%)	
Possible)	[23.44:30.42] 348	[24.03:31.06] 350	
Unrelated	5 (0.8%)	3 (0.5%)	
(Unlikely/Unrelated/Unclassifiable)	[0.25:1.80] 7	[0.10:1.35] 3	
Number of subjects discontinued	0 (0.0%) [NF] 0	0 (0.0%) [NF] 0	
due to AE			

Figure 2a: Difference in proportion of seroconversion rates with 95% confidence intervals



Figure 2b: Geometric Mean Concentration ratios with 95% confidence intervals



Serotypes	BE-PCV-14: GMC	PCV-13: GMC	GMC ratio (95% Cl)
Serotype 1	1.73	2.26	0.77 (0.67:0.88)
Serotype 3	0.85	0.7	1.23 (1.10:1.37)
Serotype 4	1.75	2.1	0.83 (0.74:0.94)
Serotype 5	1.48	1.4	1.06 (0.93:1.20)
Serotype 6B	1.69	1.8	0.94 (0.76:1.15
Serotype 7F	2.89	3.3	0.88 (0.76:1.01)
Serotype 9V	3.03	2.72	1.12 (0.95:1.31)
Serotype 14	11.18	9.52	1.18 (1.01:1.37)
Serotype 18C	2.36	2.65	0.89 (0.76:1.04)
Serotype 19A	5.39	6.02	0.89 (0.77:1.04)
Serotype 19F	5.63	6.51	0.87 (0.74:1.01)
Serotype 23F	2.03	2.19	0.92 (0.77:1.11)
Serotype 22F*	4.18	0.7 (serotype 3)	6.01 (5.26:6.87)
Serotype 33F*	1.5	0.7 (serotype 3)	2.16 (1.82:2.56)

*For serotypes 22F and 33F (which are not included in PCV-13), GMC of the BE-PCV-14 group were compared with those for the serotype in the PCV-13 group with the lowest GMC (i.e. serotype 3).

Figure 3: Reverse cumulative distribution (RCD) curves of anti-PnCPS IgG antibody concentrations for 12 common serotypes between BE-PCV-14 and PCV-13.





